MS
TLSI icon

Maven Securities’s TriSalus Life Sciences TLSI Stock Holding History

Maven Securities’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-80,681
Closed -$789K – 1270
2021
Q2 		$789K Buy
80,681
+30,681
+61% +$301K 0.03% 507
2021
Q1 		$480K Buy
+50,000
New +$507K 0.02% 687

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Maven Securities's TLSI Position: Q3 2021 in Review

Maven Securities sold out of TriSalus Life Sciences (TLSI) in Q3 2021, closing a stake of 80,681 shares — an estimated $789K sold.

Maven Securities first reported a position in TLSI in Q1 2021 and held it in 2 quarters. The position peaked at $789K in Q2 2021. 66 funds tracked by Wall St. Rank hold TLSI as of Q3 2021.

  • Maven Securities reported no remaining TriSalus Life Sciences position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 80,681 TriSalus Life Sciences shares in Q3 2021, an estimated $789K.
  • Maven Securities first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 2 quarters.
  • Maven Securities's TriSalus Life Sciences position peaked at $789K in Q2 2021.
  • 66 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.